| Literature DB >> 24779280 |
I Sinatra, L Carubia, V Marchese, L Aprea, N D'Alessandro, C Mammina, M V Torregrossa.
Abstract
INTRODUCTION: Healthcare-associated infections (HAIs) and antimicrobial resistance are well known major public health threats. The first goal of our study was to describe the prevalence of HAI, while the second goal was to describe the antibiotic consumption at our University Hospital, "P. Giaccone" in Palermo, Italy.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24779280 PMCID: PMC4718321
Source DB: PubMed Journal: J Prev Med Hyg ISSN: 1121-2233
Pattern of administration of antibiotics and indications of treatment in the surveyed patients during the PPS, 2011.
| Indication of treatment | Treated patients | Number of antimicrobials used | ||||
|---|---|---|---|---|---|---|
| 1 | > 1 | |||||
| n | % | n | % | n | % | |
| Medical prophylaxis | 27 | 16.9% | 18 | 66.6% | 9 | 33.4% |
| Surgical prophylaxis | 59 | 37.1% | 42 | 71.2% | 17 | 28.8% |
| Community infection | 58 | 36.5% | 36 | 62.1% | 22 | 37.9% |
| Healthcare-associated infection | 12 | 7.5% | 2 | 16.6% | 10 | 83.4% |
| Long-term hospital-acquired infection | 3 | 2.0% | – | – | 3 | 100.0% |
ECDC: European Centre for Disease Prevention and Control.
Total of patients treated for relative indication.
Percent of the total.
Patients receiving the indicated number of antimicrobial agents for each indication of treatment.
Percent each within category.
Distribution of antimicrobial agents (ATC 4th levels) by main indication for use, ECDC pilot point prevalence survey, 2011 (n = 223 antimicrobial agents).
| All indication | Treatment | Surgical prophylaxis | Medical prophylaxis | |
|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | |
| Antimicrobial agents, total | 223 (100) | 113 (100) | 73 (100) | 37 (100) |
| Top antimicrobial agents at ATC 4th level | ||||
| Fluoroquinolones (J01MA) | 56 (25.1) | 34 (30.1) | 12 (16.4) | 10 (27.0) |
| Third-generation cephalosporins (J01DD) | 55 (24.6) | 12 (10.6) | 35 (47.9) | 8 (21.6) |
| First-generation cephalosporins (J01DB) | 1 (0.4) | – | 1 (1.4) | – |
| Nitroimidazole derivates (P01AB) | 27 (12.1) | 11 (9.7) | 10 (13.7) | 6 (16.2) |
| Combinations of penicillins, incl.β-lactamase inhibitors (J01CR) | 18 (8.1) | 11 (9.7) | 4 (5.4) | 3 (8.1) |
| Combination of sulfonamides and trimethoprim (J01CA) | 10 (4.4) | 4 (3.5) | 2 (2.7) | 4 (10.8) |
| Macrolides (J01FA) | 9 (4.0) | 6 (5.3) | – | 3 (8.1) |
| Glycopeptide antibacterials (J01XA) | 9 (4.0) | 9 (7.9) | – | – |
| Aminoglycosides (J01GB) | 8 (3.6) | 4 (3.5) | 4 (5.4) | – |
| Penicillins, extended spectrum without anti-pseudomonal activity (J01CA) | 8 (3.6) | 6 (5.3) | 2 (2.7) | – |
| Carbapenems (J01DH) | 7 (3.1) | 6 (5.3) | 1 (1.4) | – |
| Antidiarrheals, intestinal anti-inflammatory/anti-infective agents (A07AA) | 5 (2.2) | 3 (2.6) | – | 2 (5.4) |
| Triazole derivates (J02AC) | 3 (1.3) | 3 (2.6) | – | – |
| Antimycobacterials for treatment of tuberculosis (J04A) | 2 (0.8) | 2 (1.7) | – | – |
| Tetracyclines (J01AA) | 1 (0.4) | 1 (0.8) | – | – |
| Other antibacterials (J01XX) | 3 (1.3) | 1 (0.8) | 1 (1.4) | 1 (2.7) |
Anatomical Therapeutic Chemical